Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | GLS2 | Q9UI32 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489099 | 0.91 | F7 (0.37) | CYSLTR2CYSLTR1 | |
| SCHEMBL489763 | 0.88 | ALDH1A1 (0.36) | LIPGPRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL489433 | 0.88 | LIPG (0.35) | LIPGPRSS1PRSS2PRSS3ALDH1A1 | |
| SCHEMBL6697469 | 0.80 | F7 (0.36) | ALDH1A1CYSLTR2CYSLTR1 | |
| SCHEMBL8369069 | 0.78 | CYSLTR2 (0.41) | LIPGALDH1A1CSNK1ECYSLTR2CYSLTR1 | |
| SCHEMBL489390 | 0.77 | MAPT (0.46) | PRSS1PRSS2PRSS3ALDH1A1GLS2 | |
| SCHEMBL14991821 | 0.77 | ALDH1A1 (0.53) | PRSS1PRSS2PRSS3ALDH1A1CYSLTR2 | |
| SCHEMBL14992857 | 0.77 | ALDH1A1 (0.53) | PRSS1PRSS2PRSS3ALDH1A1CYSLTR2 | |
| SCHEMBL14991937 | 0.77 | ALDH1A1 (0.53) | PRSS1PRSS2PRSS3ALDH1A1CYSLTR2 | |
| SCHEMBL14992050 | 0.77 | ALDH1A1 (0.53) | PRSS1PRSS2PRSS3ALDH1A1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515723-B1 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENT RES FOUNDATION (IN) | 2014-02-12 | — | — | EP | disclosed |
| US-8106062-B1 | Calcium channel blockers | DIAKRON PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
| EP-1542683-A2 | CALCIUM CHANNEL BLOCKERS | Diakron Pharmaceuticals, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1515723-A2 | SUBSTITUTED DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004024153-A2 | CALCIUM CHANNEL BLOCKERS | DIAKRON PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | PULLELA PHANI KUMAR (US) | 2004-03-25 | — | — | US | disclosed |
| WO-2003105854-A2 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | ORAI1, RYR2, RYR1 | LIPG 4506/4885PRSS1 2721/4885PRSS2 4121/4885 |
| US-20040058942-A1 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcuim channel blockers | ORAI1, CACNA1B, CACNA1I | LIPG 4149/4885PRSS1 2265/4885PRSS2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.